Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.72 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22450868 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2868803 | 0.92 | SLC5A2 (0.62) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2870946 | 0.91 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13153658 | 0.91 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2868243 | 0.90 | SLC5A2 (0.78) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2858077 | 0.90 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12167137 | 0.90 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL13153646 | 0.90 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13153665 | 0.90 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14878999 | 0.89 | SLC5A2 (0.62) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| US-20210283156-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-09-16 | — | — | US | claimed |
| US-20200069713-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2020-03-05 | — | — | US | claimed |
| US-20170020907-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-01-26 | — | — | US | claimed |
| US-20160158264-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-06-09 | — | — | US | claimed |
| EP-2846797-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2015-03-18 | — | — | EP | claimed |
| CN-104138370-A | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | BOEHRINGER INGELHEIM INT | 2014-11-12 | — | — | CN | claimed |
| US-8846613-B2 | Pharmaceutical combinations for the treatment of metabolic disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | claimed |
| EP-2698152-A1 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | Boehringer Ingelheim International GmbH (DE) | 2014-02-19 | — | — | EP | claimed |
| US-20140038888-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | claimed |
| CN-102316875-A | SGLT-2 inhibitors for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance or hyperglycemia | BOEHRINGER INGELHEIM INT | 2012-01-11 | — | — | CN | claimed |
| EP-2396005-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | Boehringer Ingelheim International GmbH (DE) | 2011-12-21 | — | — | EP | claimed |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | claimed |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | claimed |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| WO-2010092123-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | WO | claimed |
| US-7776830-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-17 | — | — | US | claimed |
| CN-101784270-A | Pharmaceutical compositions comprising glucopyranosyl-substituted benzene derivatives | BOEHRINGER INGELHEIM INT | 2010-07-21 | — | — | CN | claimed |
| EP-2187879-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | DPP4, SLC5A1, DPP7 | SLC5A2 5/4885SLC5A1 2/4885ADRA2A 489/4885 |
| US-20170020907-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20210283156-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20200069713-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20140038888-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | SLC5A1, SLC5A2, CPT1A | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 168/4885 |
| US-20160158264-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 569/4885 |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, UGT1A4, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.